# Natural killer T (NKT) cells

Source: https://onco.cc/terms/nkt-cells/  
OnCo record `nkt-cells` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Natural killer T cells are T cells, not a cross between two cell types, and their receptors recognise fat-based molecules shown on a protein called CD1d rather than the protein fragments shown on HLA. Despite the similar name they are a different family from natural killer cells.

## Summary

NKT cells carry a rearranged T-cell receptor, and some also carry receptors usually associated with natural killer cells, but an NK-associated surface marker does not define the family. A review describes their semi-invariant alpha-beta T-cell receptors as recognising CD1d-presented glycolipids, including a mammalian glycosphingolipid and microbial glycuronylceramides (Bendelac et al., 2007). CD1d displays lipid and glycolipid antigens, and the crystal structure of human CD1d with the synthetic glycolipid alpha-galactosylceramide showed the lipid tails fitting inside the groove (Koch et al., 2005). In mouse experiments, Valpha14 NKT cells were activated by a defined glycosylceramide in a CD1d-dependent, receptor-mediated way (Kawano et al., 1997). Type I, or invariant, NKT cells use a strongly shared alpha-chain arrangement with variable beta-chain junctions, found in mouse (Valpha14-Jalpha281) and in a homologous human form (Valpha24-JQ) (Lantz and Bendelac, 1994). Type II NKT cells are more diverse: in mice lacking class II presentation, CD4 T cells with a diverse receptor repertoire included a subset that recognised CD1 (Cardell et al., 1995). 'Invariant' does not mean every chain or every function is identical.

## Fields

- Kind: Term
- Last checked: 2026-11-10
- Also known as: NKT cells; iNKT cells; invariant NKT cells

## Notes

- Function depends on the subset and the stimulus. In fresh human blood, lipid-loaded CD1d tetramers separated two subsets of CD1d-restricted T cells that differed in cytokine production and cytotoxic activation, and antigenic stimulation induced cytokines but not perforin whereas inflammatory factors enhanced perforin (Gumperz et al., 2002). In mouse sarcoma and melanoma-metastasis models, tumour rejection was a specialised function of liver-derived NKT cells and mainly of the CD4-negative fraction, while thymus-derived NKT cells were impaired, in part through interleukin-4 production (Crowe et al., 2005). So 'NKT' alone cannot mean protection against cancer, even within one species. An engineered receptor is a separate recognition route: CAR-NKT, CAR-NK and CAR-T are different cell families, and native and engineered recognition have to be measured separately. A phase 1 trial reported interim results for autologous NKT cells engineered to express a GD2-specific CAR with interleukin-15 in three children with neuroblastoma (NCT03294954): no dose-limiting toxicities were observed and one patient had an objective response (Heczey et al., 2020). Separate trials illustrate the other two families: an anti-CD19 CAR-NK product made from cord blood was given to 11 patients with relapsed or refractory CD19-positive cancers in a phase 1 and 2 trial (Liu et al., 2020), and tisagenlecleucel, an anti-CD19 CAR-T therapy, was given to 75 evaluable children and young adults in a phase 2 study in which the overall remission rate within 3 months was 81 per cent (Maude et al., 2018). Those trials concern other cells, diseases and products and say nothing about NKT cells.
- A tetramer loaded with a defined CD1d antigen identifies the cells that bind that complex, so a negative result does not count cells with other specificities, and a gate of NK-marker-positive T cells (sometimes called NKT-like) needs its operational definition stated. Counting such cells does not establish tumour killing, and a change in classical HLA display does not show that CD1d, its antigen or an effective NKT response is present.
- An NK-associated marker is insufficient to define an NKT cell. Benlagha et al. (2000) identified glycolipid-reactive T cells with CD1d1-alpha-galactosylceramide tetramers, including an NK1.1-negative population in mice, while natural killer cells did not bind those tetramers. This is a studied glycolipid-reactive subset, not a universal detection test for all type II NKT cells. NKT cells can carry NK-associated receptors, but a marker-positive T-cell gate and a defined CD1d-reactive T-cell population are different operational definitions.
- In the alpha-galactosylceramide example, lipid tails sit within CD1d and the sugar head group forms part of the surface that a T-cell receptor can recognize. This is recognition of a displayed CD1d-lipid complex, rather than free lipid. Le Nours et al. (2016) described human atypical NKT receptors that contacted the same CD1d-lipid target in different ways from the more familiar type I receptors. A simple receptor-above-lipid sketch therefore does not specify the docking angle, chain contacts or target range of every NKT subset. Comparing that display with peptide-HLA concerns the target form; it does not make NKT and NK the same family or establish uniform function.

## Sources

- An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans.: https://doi.org/10.1084/jem.180.3.1097
- CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice.: https://doi.org/10.1084/jem.182.4.993
- CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides.: https://doi.org/10.1126/science.278.5343.1626
- Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining.: https://doi.org/10.1084/jem.20011786
- Differential antitumor immunity mediated by NKT cell subsets in vivo.: https://doi.org/10.1084/jem.20050953
- The crystal structure of human CD1d with and without alpha-galactosylceramide.: https://doi.org/10.1038/ni1225
- The biology of NKT cells.: https://doi.org/10.1146/annurev.immunol.25.022106.141711
- Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.: https://doi.org/10.1038/s41591-020-1074-2
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.: https://doi.org/10.1056/nejmoa1910607
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.: https://doi.org/10.1056/nejmoa1709866
- Benlagha et al., 2000: Identification of glycolipid antigen-specific T cells: https://doi.org/10.1084/jem.191.11.1895
- Atypical natural killer T-cell receptor recognition of CD1d-lipid antigens.: https://doi.org/10.1038/ncomms10570

## Connected records

- technologies: [CAR-NK & CAR-macrophage](https://onco.cc/technologies/car-nk-macrophage/)
- terms: [Immune system](https://onco.cc/terms/immune-system/), [NK cell](https://onco.cc/terms/nk-cell/), [T cell](https://onco.cc/terms/t-cell/)

---
JSON: https://onco.cc/api/v1/entities/nkt-cells.json